Advertisement
Canada markets closed
  • S&P/TSX

    22,259.47
    +312.06 (+1.42%)
     
  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     
  • DOW

    38,852.27
    +176.59 (+0.46%)
     
  • CAD/USD

    0.7320
    +0.0011 (+0.15%)
     
  • CRUDE OIL

    78.69
    +0.58 (+0.74%)
     
  • Bitcoin CAD

    86,788.59
    -363.71 (-0.42%)
     
  • CMC Crypto 200

    1,364.74
    +52.11 (+3.97%)
     
  • GOLD FUTURES

    2,332.90
    +24.30 (+1.05%)
     
  • RUSSELL 2000

    2,060.67
    +24.95 (+1.23%)
     
  • 10-Yr Bond

    4.4890
    -0.0110 (-0.24%)
     
  • NASDAQ futures

    18,185.50
    +184.75 (+1.03%)
     
  • VOLATILITY

    13.49
    0.00 (0.00%)
     
  • FTSE

    8,213.49
    +41.34 (+0.51%)
     
  • NIKKEI 225

    38,236.07
    -38.03 (-0.10%)
     
  • CAD/EUR

    0.6793
    +0.0006 (+0.09%)
     

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update

Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.

NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, May 2, 2024, to discuss its financial results and corporate update for the quarter ending March 31, 2024.

The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. To participate in the live call, please register by clicking on the following link (registration link) and you will be provided with dial-in details. The replay of the call will be available for 3 months.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

ADVERTISEMENT

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx

Investors
Joshua Higa
(415) 475-6370

Media
Carolyn Wang
(415) 225-5050